Pacylex Presents Evidence Supporting Advancement of PCLX-001 for Treatment of AML at AACR 2022
New data on PCLX-001 being presented at AACR showing the potential for N-myristoylation inhibition to treat for AML with in vitro and animal model data: PCLX-001 dramatically reduces AML stem cells in the bone marrow.
